Guest User
The Global Anemia Drugs Market is growing with the sound pace. According to a recent study report published by the Market Research Future, the global anemia drugs market is booming and is expected to gain prominence over the forecast period growing rapidly .The market is forecasted to demonstrate a spectacular growth by 2022, surpassing its previous growth records in terms of value with a sound CAGR during the anticipated period (2017 – 2022).
The global market for anemia drugs is growing at a good rate. The market driving factors are growth of geriatric population, increasing awareness, increasing focus of social healthcare on women health and particularly anemia, rise in accidents and cancer, rise in other risk factors such as diabetes, modern lifestyle induced stress, poor nutritional habits, rise in lactating and pregnant women in developing regions, intestinal infections etc.
The market constraints are poor absorption of drugs especially intravenous iron and the side effects associated with the treatment. Better nutrition due to rising per capita income is also a market limiting factor for anemic drugs.
The Anemia Drugs Marketis expected to be around US$21.4 billion and is expected to grow at a CAGR of 8.4% to reach US$34.7 billion by the end of forecast period.
Key Players for Global Anemia Drugs Market
Top Companies ofAnemia Drugs Listas:
Amgen Inc., GlaxoSmithKline plc, Bluebird bio, Biocon, GlycoMimetics Inc., Regen biopharma Inc., Bayer AG, Acceleron Pharma, Eli Lilly and company are some of the prominent players at the forefront of competition in the global anemia drugs market and are profiled in MRFR Analysis.
Characterized by the presence of several well-established and small players, the global anemia drugs market appears to be highly competitive and fragmented. International players who are increasingly expanding their footprint in the developing economies, makes it difficult for regional vendors to compete with them, especially in terms of features such as product portfolios, quality, and pricing. The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The intense competition prevalent in the market dictates the consolidation among marketers.
Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.
Segments for Global Anemia Drugs Market
Global anemia drugs market has been segmented on the basis of anemia type which comprises iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia pernicious anemia and others. On the basis of route of administration; market is segmented into oral and injectable. On the basis of gender; market is segmented into male and female. On the basis of product type; market is segmented into biologics and non-biologics. On the basis of end users; market is segmented into hospitals, self-administered and others.
Global anemia drugs market has been segmented on the basis of anemia type which comprises iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia pernicious anemia and others. On the basis of route of administration; market is segmented into oral and injectable. On the basis of gender; market is segmented into male and female. On the basis of product type; market is segmented into biologics and non-biologics. On the basis of end users; market is segmented into hospitals, self-administered and others.
Regional Analysis for Global Anemia Drugs Market
On the regional backgrounds the Americas leads the global market for anemia drugs owing to huge patient population, increasing healthcare expenditures and presence of the developed economies like U.S. and Canada within the region. Following, the same trends Europe is second in the market. The Asia Pacific region is the fastest growing region due to the developing economies like India and China. Middle East and Africa have the least market share, especially due to the presence of poor economies within the African region. Moreover, stringent government policies within the region are restraining the market growth within the region. On the hand, Middle East leads the regional market due to the presence of developed economies like Kuwait, Qatar, and others within the region and rising healthcare expenses.
